LIPS method for the detection of SARS-CoV-2 antibodies to spike and nucleocapsid proteins
© 2020 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim..
Profiling antibodies to SARS-CoV-2 can help to assess potential immune response after COVID-19 disease. Luciferase IP system (LIPS) assay is a sensitive method for quantitative detection of antibodies to antigens in their native conformation. We here describe LIPS to detect antibody responses to SARS-CoV-2 spike (S) and nucleocapsid (N) proteins in COVID-19 patients. The antibodies targeted both S and N fragments and gave a high assay sensitivity by identifying 26 out of 26 COVID-19 patients with N antigen or with three protein fragments when combined into a single reaction. The assay correlated well with ELISA method and was specific to COVID-19 as we saw no reactivity among uninfected healthy controls. Our results show that LIPS is a rapid and measurable method to screen antibody responses against SARS-CoV-2 antigens.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:50 |
|---|---|
| Enthalten in: |
European journal of immunology - 50(2020), 8 vom: 01. Aug., Seite 1234-1236 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Haljasmägi, Liis [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies |
|---|
| Anmerkungen: |
Date Completed 30.11.2020 Date Revised 16.09.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/eji.202048715 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM311627617 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM311627617 | ||
| 003 | DE-627 | ||
| 005 | 20231225142645.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/eji.202048715 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1038.xml |
| 035 | |a (DE-627)NLM311627617 | ||
| 035 | |a (NLM)32584420 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Haljasmägi, Liis |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a LIPS method for the detection of SARS-CoV-2 antibodies to spike and nucleocapsid proteins |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 30.11.2020 | ||
| 500 | |a Date Revised 16.09.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2020 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim. | ||
| 520 | |a Profiling antibodies to SARS-CoV-2 can help to assess potential immune response after COVID-19 disease. Luciferase IP system (LIPS) assay is a sensitive method for quantitative detection of antibodies to antigens in their native conformation. We here describe LIPS to detect antibody responses to SARS-CoV-2 spike (S) and nucleocapsid (N) proteins in COVID-19 patients. The antibodies targeted both S and N fragments and gave a high assay sensitivity by identifying 26 out of 26 COVID-19 patients with N antigen or with three protein fragments when combined into a single reaction. The assay correlated well with ELISA method and was specific to COVID-19 as we saw no reactivity among uninfected healthy controls. Our results show that LIPS is a rapid and measurable method to screen antibody responses against SARS-CoV-2 antigens | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a LIPS | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a antibodies | |
| 650 | 4 | |a luciferase immunoprecipitation | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 650 | 7 | |a Nucleocapsid Proteins |2 NLM | |
| 700 | 1 | |a Remm, Anu |e verfasserin |4 aut | |
| 700 | 1 | |a Rumm, Anna Pauliina |e verfasserin |4 aut | |
| 700 | 1 | |a Krassohhina, Ekaterina |e verfasserin |4 aut | |
| 700 | 1 | |a Sein, Hanna |e verfasserin |4 aut | |
| 700 | 1 | |a Tamm, Anu |e verfasserin |4 aut | |
| 700 | 1 | |a Kisand, Kai |e verfasserin |4 aut | |
| 700 | 1 | |a Peterson, Pärt |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of immunology |d 1971 |g 50(2020), 8 vom: 01. Aug., Seite 1234-1236 |w (DE-627)NLM000108723 |x 1521-4141 |7 nnns |
| 773 | 1 | 8 | |g volume:50 |g year:2020 |g number:8 |g day:01 |g month:08 |g pages:1234-1236 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/eji.202048715 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 50 |j 2020 |e 8 |b 01 |c 08 |h 1234-1236 | ||